Cogent Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
COGT Nasdaq 8731 https://www.cogentbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cogent Biosciences Inc

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor - Apr 9th, 2024 1:00 pm
COGT Reports Full Year 2023 Financial Results and Business Highlights - Feb 28th, 2024 9:32 am
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - Feb 26th, 2024 1:00 pm
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis - Feb 22nd, 2024 7:30 pm
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement - Feb 14th, 2024 12:00 pm
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting - Feb 5th, 2024 2:00 pm
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics - Jan 9th, 2024 1:00 pm
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference - Jan 2nd, 2024 1:00 pm
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) - Dec 11th, 2023 12:55 pm
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - Dec 9th, 2023 6:30 pm
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium - Dec 7th, 2023 2:00 pm
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting - Dec 4th, 2023 1:00 pm
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium - Nov 29th, 2023 1:00 pm
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Deliver On Growth Plans? - Nov 27th, 2023 5:01 pm
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results - Nov 2nd, 2023 1:00 pm
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 14th, 2023 4:30 pm
After losing 15% in the past year, Cogent Biosciences, Inc. (NASDAQ:COGT) institutional owners must be relieved by the recent gain - Aug 13th, 2023 12:51 pm
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results - Aug 8th, 2023 12:00 pm
Analysts Say These 2 Stocks Are Their ‘Top Picks’ for the Rest of 2023 - Jul 10th, 2023 11:35 pm
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock - Jun 9th, 2023 8:01 pm